An interventional study of Education Program Using Gamification on GDM in Gestational Diabetes Mellitus (GDM), sponsored by Yeditepe University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-07-16.
Sponsored by Yeditepe University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Diabetes, Gestational with a site in Turkey — 9 open to participants now, 12 under way, none of them phase 3. Diabetes, Gestational · Turkey.
Among the 52 studies in Diabetes, Gestational with a site in Turkey, this one is the 16th largest by planned enrollment of the 28 interventional ones that give a count, is one of 7 that started in 2025, is one of 28 with no phase, reaches primary completion later than 9 of the 11 other live ones, and was the 41st registered.
878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.
Browse Diabetes, Gestational studies →9 of the 52 studies in Diabetes, Gestational with a site in Turkey are open now. Recruiting first, the newest first:
Burak Deniz Aydoğdu · Sites in Turkey
Ages 18–50 · Women only
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization · Sites in Turkey
Ages 18–50 · Women only · Healthy volunteers
Izmir Ataturk Training and Research Hospital · Sites in Turkey
Ages 18–45 · Women only · Healthy volunteers
Izmir Katip Celebi University · Sites in Turkey
Ages 18+ · Women only
Umraniye Education and Research Hospital · Sites in Turkey
Ages 18–39 · Women only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 78 is below the median of 110 across 563 interventional studies indexed under Diabetes, Gestational.
Median enrollment 85 across the 28 interventional studies, 100 across the 24 observational. Of the 37 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 52 has an industry lead sponsor. The 10 most frequent:
Yeditepe University is the lead sponsor of 132 studies on the registry; 29 are open to participants now.
Yeditepe University has 1 study filed under Diabetes, Gestational — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetes, Gestational with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07750431Samsun UniversityThe Role of Progesterone Membrane Receptors in the Development of Gestational Diabetes Mellitus | 2027-01-01 |
| NCT07067411Yeditepe UniversityGamified Education for Diabetes Self-Management in GDM | 2027-07-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 52 studies in Diabetes, Gestational with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Gestational diabetes mellitus (GDM) is a serious public health problem characterized by hyperglycemia that develops during pregnancy and causes significant short- and long-term health risks for both the mother and the fetus. Lifestyle changes, especially appropriate diet and exercise practices and glycemic control are among the basic approaches in GDM management. However, the individual's adoption and sustainability of these approaches are often insufficient, and the individual's participation in treatment and motivation levels may be limited.
When the literature is examined, it has been proven that gamification-based interventions, especially in individuals with type 2 diabetes, have positive effects such as increasing the level of knowledge, encouraging physical activity and improving glycemic control. However, the lack of gamification-based nursing interventions specific to women with GDM is striking. The fact that there is no standardized nursing protocol specific to GDM management in our country makes the literature gap in this area even more evident.
This study aims to develop health behaviors in individuals with GDM through a gamified training program to be developed based on the Information-Motivation-Behavioral Skills (IMB) model. Thanks to the innovative structure of gamification, it is aimed not only to increase the knowledge level of individuals, but also to increase their motivation and make behavioral changes permanent. Thus, the active participation of the individual in the treatment process will be encouraged and the self- management skills will be strengthened.
This research will be an important step in terms of the integration of digitalization and patient-centered approaches in nursing practices, as well as indirectly contributing to the protection and development of public health. While the training program has the potential to increase the quality of life at the individual level, it will also allow the development of an original and structured nursing care intervention that can be used in GDM management.
This study aims to fill an important gap in the literature, to disseminate innovative practices in the field of nursing, and to support healthy pregnancy outcomes at the social level. For this reason, the purpose of the research was planned to examine the effect of the training program applied to women with gestational diabetes with the gamification technique based on the information-motivation-behavior (IMB) model on diabetes self-management.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
39 participants were assigned as a result of randomization. Participants receiving care through games.
Behavioral: Education Program Using Gamification on GDM
39 participants were assigned as a result of randomization. Receiving only routine care.
The five games planned to be used in the study are; "What is Gestational Diabetes?", "Nutrition Education", "Complication Precautions", "Medical Treatment Applications" and "Physical Activity". The creation and implementation of these games will be done through the "Genially" platform. The Genially platform is an easy-to-use and free web tool used to create interactive visual content. The platform includes features such as sharing or downloading via website, social media or e-mail by adding animations, effects, sounds and interactive elements. In addition, the performances of the people who share the created content can be tracked and feedback can be obtained. At the beginning of the games planned to be used in the study, an informative video of not more than five minutes on the subject created by the researcher will be shared. National and international guidelines will be taken into consideration in the creation of these videos. One day after the informative video is
Self-Efficacy Scale in Gestational Diabetes
The validity and reliability of the "Self-Efficacy Scale in Gestational Diabetes" was determined by Polat and Ünsal Avdal and it was concluded that it is a valid and reliable measurement tool. The Self-Efficacy Scale in Gestational Diabetes (SESGD) is a five-point Likert-type scale consisting of four sub-dimensions. The sub-dimensions of the scale are; ''Diet-Weight Management'', ''Complication Precautions'', ''Adherence to Nutrition Education'' and ''Medical Treatment Applications''. The total Cronbach alpha value of the scale was determined as 0.654. The scale includes positive and negative statements. Reverse and forward coding is done during the analysis. It can be thought that as the score to be obtained from the scale increases as a result of the coding of positive and negative statements in the scale, the individual's self-efficacy will increase and that he/she will be able to effectively take care of himself/herself as a result of the education he/she receives.
Time frame: through study completion, an average of 1 year
International Physical Activity Questionnaire Short Form-Turkish version (IPAQ)
For the analysis of IPAQ data, it is evaluated as "walking: 3.3 MET", "moderate physical activity: 4.0 MET", "vigorous physical activity: 8.0 MET". Daily and weekly physical activity levels are calculated using these values. As the MET value increases, the physical activity level increases.
Time frame: through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2025; primary completion for Jul 2027, 23 months later.
Of 306 non-industry interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 23 months is below that.
Counting every sponsor, half of 309 studies reached it within 28 months; a quarter within 13 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.